The Delhi High Court on Monday extended its interim order lifting ban on fixed dose combination (FDC) medicines of some pharmaceutical companies, which had got relief last week, till March 28.
Several other pharma companies, which also filed appeals against the Centre’s notification, were not granted a similar relief but have been given “assurance” that no coercive action will be taken against them till the next date of hearing.
- Meeting to discuss construction of ‘longest’ cycling track in Mumbai
- ‘Nek Chand’s art is unique & distinct’
- Brush with canvas: ‘Art of any form must make us think & reflect’
- Will the Ravanas be ready in time for Dussehra? Drive by South civic body poses worry for artisans
- Friends, colleagues remember KJ Singh
- Women inmates bring their ordeal to the stage
In an affidavit, the government said that lifting the ban would be “against public interest and patient safety”. It claimed that the pharma companies were interested only in profit.
As of Monday, 112 petitions had been filed before the Delhi HC challenging the Centre’s March 10 notification banning more than 300 FDC drugs. The companies claim that the notification was issued without following the due process of issuing them a show-cause notice or hearing them.
The court had last week stayed operation of the Centre’s ban on some FDC drugs of 30 pharma companies. ENS